Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Matthew Ho, Giada Bianchi & Kenneth C. Anderson. (2020) Proteomics-inspired precision medicine for treating and understanding multiple myeloma. Expert Review of Precision Medicine and Drug Development 5:2, pages 67-85.
Read now
Read now
Matthew Ho Zhi Guang, Amanda McCann, Giada Bianchi, Li Zhang, Paul Dowling, Despina Bazou, Peter O’Gorman & Kenneth C. Anderson. (2018) Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’. Leukemia & Lymphoma 59:3, pages 542-561.
Read now
Read now
Barbara Muz, Hubert D. Kusdono, Feda Azab, Pilar de la Puente, Cinzia Federico, Mark Fiala, Ravi Vij, Noha N. Salama & Abdel Kareem Azab. (2017) Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance. Leukemia & Lymphoma 58:12, pages 2916-2925.
Read now
Read now
Barbara Muz, Rachel Nicole Ghazarian, Monica Ou, Micah John Luderer, Hubert Daniel Kusdono & Abdel Kareem Azab. (2016) Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Design, Development and Therapy 10, pages 217-226.
Read now
Read now
Barbara Muz, Pilar de la Puente, Feda Azab & Abdel Kareem Azab. (2015) The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia 3, pages 83-92.
Read now
Read now
Articles from other publishers (64)
Hamid A. Bakshi, Michella Mkhael, Hakkim L. Faruck, Asad Ullah Khan, Alaa A.A. Aljabali, Vijay Mishra, Mohamed El-Tanani, Nitin B. Charbe & Murtaza M. Tambuwala. (2024) Cellular signaling in the hypoxic cancer microenvironment: Implications for drug resistance and therapeutic targeting. Cellular Signalling 113, pages 110911.
Crossref
Crossref
Yu Feng, Jingcao Huang, Fangfang Wang, Zhimei Lin, Hongmei Luo, Qian Li, Xin Wang, Xiang Liu, Xinyu Zhai, Qianwen Gao, Lingfeng Li, Yue Zhang, Jingjing Wen, Li Zhang, Ting Niu & Yuhuan Zheng. (2023) Methylcrotonyl-CoA carboxylase subunit 1 (MCCA) regulates multidrug resistance in multiple myeloma. Life Sciences 333, pages 122157.
Crossref
Crossref
Ketki Bhise, Navnath S. Gavande & Arun K. Iyer. (2023) Leveraging hypoxia in triple-negative breast cancer as a promising treatment strategy. Drug Discovery Today 28:11, pages 103761.
Crossref
Crossref
Maria Ochiai, Sara Fierstein, Farouq XsSali, Nicholas DeVito, Laura R. Purkey, Rebecca May, Abraham Correa-Medina, Mary Kelley, Thomas D. Page & Kathleen DeCicco-Skinner. (2023) Unlocking Drug Resistance in Multiple Myeloma: Adipocytes as Modulators of Treatment Response. Cancers 15:17, pages 4347.
Crossref
Crossref
Katie T. Skinner, Antara M. Palkar & Andrew L. Hong. (2023) Genetics of ABCB1 in Cancer. Cancers 15:17, pages 4236.
Crossref
Crossref
Mei-Chi Su, Susheel Kumar Nethi, Pavan Kumar Dhanyamraju & Swayam Prabha. (2023) Nanomedicine Strategies for Targeting Tumor Stroma. Cancers 15:16, pages 4145.
Crossref
Crossref
Emanuele Cencini, Anna Sicuranza, Sara Ciofini, Alberto Fabbri, Monica Bocchia & Alessandro Gozzetti. (2023) Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications. Current Oncology 30:7, pages 6111-6133.
Crossref
Crossref
Jian Gao, Jian Zhou, Menghui Zhang, Yan Zhang, Yindi Zeng, Shihao Li, Kailin Xu & Ruosi Yao. (2023) A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling. Molecular and Cellular Biochemistry.
Crossref
Crossref
Piotr Kulig, Sławomir Milczarek, Estera Bakinowska, Laura Szalewska, Bartłomiej Baumert & Bogusław Machaliński. (2023) Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives. Cancers 15:3, pages 963.
Crossref
Crossref
Staci L. Haney & Sarah A. Holstein. (2022) Targeting the Isoprenoid Biosynthetic Pathway in Multiple Myeloma. International Journal of Molecular Sciences 24:1, pages 111.
Crossref
Crossref
Jason W. Y. Kan, Clare S. W. Yan, Iris L. K. Wong, Xiaochun Su, Zhen Liu, Tak Hang Chan & Larry M. C. Chow. (2022) Discovery of a Flavonoid FM04 as a Potent Inhibitor to Reverse P-Glycoprotein-Mediated Drug Resistance in Xenografts and Improve Oral Bioavailability of Paclitaxel. International Journal of Molecular Sciences 23:23, pages 15299.
Crossref
Crossref
Parisa Maleki Dana, Fatemeh Sadoughi, Zatollah Asemi & Bahman Yousefi. (2022) The role of polyphenols in overcoming cancer drug resistance: a comprehensive review. Cellular & Molecular Biology Letters 27:1.
Crossref
Crossref
Hytham H. Gadalla, Seongsoo Lee, Hyungjun Kim, Abigail T. Armstrong, Dina Fathalla, Fawzia Habib, Hyunyoung Jeong, Wooin Lee & Yoon Yeo. (2022) Size optimization of carfilzomib nanocrystals for systemic delivery to solid tumors. Journal of Controlled Release 352, pages 637-651.
Crossref
Crossref
Inge Oudaert, Arne Van der Vreken, Anke Maes, Elke De Bruyne, Kim De Veirman, Karin Vanderkerken & Eline Menu. (2022) Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma. Experimental Hematology & Oncology 11:1.
Crossref
Crossref
Bernard Gallez. (2022) The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia. Frontiers in Pharmacology 13.
Crossref
Crossref
Laura O. Walter, Mariana F. Maioral, Lisandra O. Silva, Douglas B. Speer, Sanjay C. Campbell, Winklet Gallimore, Miriam B. Falkenberg & Maria Cláudia Santos‐Silva. (2022)
Involvement of the
NF‐κB
and
PI3K
/Akt/
mTOR
pathways in cell death triggered by stypoldione, an o‐quinone isolated from the brown algae
Stypopodium zonale
. Environmental Toxicology 37:6, pages 1297-1309.
Crossref
Crossref
Mirushan Arunasalam, Vivian Chong, Sharanya Ranee Mareshvaran, Venessa Ngui Fern Yee, Anand Gaurav, Shamala Salvamani, Crystale Siew Ying Lim & Baskaran Gunasekaran. (2022) Identification of natural product inhibitors of de novo lipogenesis enzymes as an anti-cancer strategy: An in silico approach. Asia Pacific Journal of Molecular Biology and Biotechnology, pages 1-14.
Crossref
Crossref
Mei Sun, Xingxiu Chen & Zhibo Yang. (2022) Single cell mass spectrometry studies reveal metabolomic features and potential mechanisms of drug-resistant cancer cell lines. Analytica Chimica Acta 1206, pages 339761.
Crossref
Crossref
Srijit Das, Norsham Juliana, Noor Anisah Abu Yazit, Sahar Azmani & Izuddin Fahmy Abu. (2022) Multiple Myeloma: Challenges Encountered and Future Options for Better Treatment. International Journal of Molecular Sciences 23:3, pages 1649.
Crossref
Crossref
Zhu Zeng, Yong Zhao, QingYong Chen, Shuai Zhu, Yi Niu, Zeng Ye, Ping Hu, Ding Chen, Peng Xu, Jinghuang Chen, Chaojie Hu, Yuhang Hu, Fengyu Xu, Jiang Tang, Fan Wang, Shengbo Han, Mengqi Huang, Chunyou Wang & Gang Zhao. (2021) Hypoxic exosomal HIF-1α-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis. Oncogene 40:36, pages 5505-5517.
Crossref
Crossref
Junsha An, Cheng Peng, Hailin Tang, Xiuxiu Liu & Fu Peng. (2021) New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. International Journal of Molecular Sciences 22:17, pages 9644.
Crossref
Crossref
Rachel L. Mynott & Craig T. Wallington-Beddoe. (2021) Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma. ACS Pharmacology & Translational Science 4:3, pages 1050-1065.
Crossref
Crossref
Anastazja Poczta, Aneta Rogalska & Agnieszka Marczak. (2021) Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies—Current Research and Clinical Approaches. Journal of Clinical Medicine 10:9, pages 1841.
Crossref
Crossref
Rachel L. Mynott & Craig T. Wallington-Beddoe. (2021) Inhibition of P-Glycoprotein Does Not Increase the Efficacy of Proteasome Inhibitors in Multiple Myeloma Cells. ACS Pharmacology & Translational Science 4:2, pages 713-729.
Crossref
Crossref
Marián Babinčák, Rastislav Jendželovský, Ján Košuth, Martin Majerník, Jana Vargová, Kamil Mikulášek, Zbyněk Zdráhal & Peter Fedoročko. (2021) Death Receptor 5 (TNFRSF10B) Is Upregulated and TRAIL Resistance Is Reversed in Hypoxia and Normoxia in Colorectal Cancer Cell Lines after Treatment with Skyrin, the Active Metabolite of Hypericum spp.. Cancers 13:7, pages 1646.
Crossref
Crossref
Georgina E. Wood, Helen Hockings, Danielle M. Hilton & Stéphanie Kermorgant. (2021) The role of MET in chemotherapy resistance. Oncogene 40:11, pages 1927-1941.
Crossref
Crossref
Guendalina Zuccari, Sara Baldassari, Silvana Alfei, Barbara Marengo, Giulia Elda Valenti, Cinzia Domenicotti, Giorgia Ailuno, Carla Villa, Leonardo Marchitto & Gabriele Caviglioli. (2021) D-α-Tocopherol-Based Micelles for Successful Encapsulation of Retinoic Acid. Pharmaceuticals 14:3, pages 212.
Crossref
Crossref
Sara Ovejero & Jerome Moreaux. (2021) Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma. Exploration of Targeted Anti-tumor Therapy.
Crossref
Crossref
Sara Ovejero & Jerome Moreaux. (2021) Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma. Exploration of Targeted Anti-tumor Therapy.
Crossref
Crossref
Asieh Emami Nejad, Simin Najafgholian, Alireza Rostami, Alireza Sistani, Samaneh Shojaeifar, Mojgan Esparvarinha, Reza Nedaeinia, Shaghayegh Haghjooy Javanmard, Marjan Taherian, Mojtaba Ahmadlou, Rasoul Salehi, Bahman Sadeghi & Mostafa Manian. (2021) The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell International 21:1.
Crossref
Crossref
Wenyu Wang, Youngjin Han, Hyun A Jo, Juwon Lee & Yong Sang Song. (2020) Non-coding RNAs shuttled via exosomes reshape the hypoxic tumor microenvironment. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Wei Wang, Mei Wang, Jing Xu, Fei Long & Xianbao Zhan. (2020) Overexpressed GATA3 enhances the sensitivity of colorectal cancer cells to oxaliplatin through regulating MiR-29b. Cancer Cell International 20:1.
Crossref
Crossref
Shuai Jiang, Ming Xiao, Wen Sun, Daniel Crespy, Volker Mailänder, Xiaojun Peng, Jiangli Fan & Katharina Landfester. (2020) Synergistic Anticancer Therapy by Ovalbumin Encapsulation‐Enabled Tandem Reactive Oxygen Species Generation. Angewandte Chemie International Edition 59:45, pages 20008-20016.
Crossref
Crossref
Shuai Jiang, Ming Xiao, Wen Sun, Daniel Crespy, Volker Mailänder, Xiaojun Peng, Jiangli Fan & Katharina Landfester. (2020) Synergistic Anticancer Therapy by Ovalbumin Encapsulation‐Enabled Tandem Reactive Oxygen Species Generation. Angewandte Chemie 132:45, pages 20183-20191.
Crossref
Crossref
Wenhao Zhong, Xinyu Zhang, Meng Zhao, Jun Wu & Dongjun Lin. (2020) Advancements in nanotechnology for the diagnosis and treatment of multiple myeloma. Biomaterials Science 8:17, pages 4692-4711.
Crossref
Crossref
Mateusz Adam Krzyscik, Małgorzata Zakrzewska & Jacek Otlewski. (2020) Site-Specific, Stoichiometric-Controlled, PEGylated Conjugates of Fibroblast Growth Factor 2 (FGF2) with Hydrophilic Auristatin Y for Highly Selective Killing of Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1 (FGFR1). Molecular Pharmaceutics 17:7, pages 2734-2748.
Crossref
Crossref
Erin Clapper, Sicong Wang, Prahlad V. Raninga, Giovanna Di Trapani & Kathryn F. Tonissen. (2020) Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment. Antioxidants 9:3, pages 207.
Crossref
Crossref
Vanessa Pinto, Rui Bergantim, Hugo R. Caires, Hugo Seca, José E. Guimarães & M. Helena Vasconcelos. (2020) Multiple Myeloma: Available Therapies and Causes of Drug Resistance. Cancers 12:2, pages 407.
Crossref
Crossref
Ana Bela Sarmento-Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, Thomas Efferth & Ioannis P. Trougakos. (2019) The emergence of drug resistance to targeted cancer therapies: Clinical evidence. Drug Resistance Updates 47, pages 100646.
Crossref
Crossref
Juan Li, Lei Zheng, Mi Yan, Jing Wu, Yongqing Liu, Xiaona Tian, Wen Jiang, Lu Zhang & Rongmei Wang. (2019) Activity and mechanism of flavokawain A in inhibiting permeability‑glycoprotein expression in paclitaxel resistance of lung cancer. Oncology Letters.
Crossref
Crossref
Teodora Alexa-Stratulat, Milica Pešić, Ana Čipak Gašparović, Ioannis P. Trougakos & Chiara Riganti. (2019) What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg. Drug Resistance Updates 46, pages 100643.
Crossref
Crossref
Feifei Wang, Zhewen Zhang, Wing Leung, Jing Chen, Juan Yi, Chunmei Ying, Minmin Yuan, Mingyan Wang, Na Zhang, Xuemin Qiu, Ling Wang & Hulai Wei. (2019) Hydroxychloroquine reverses the drug resistance of leukemic K562/ADM�cells by inhibiting autophagy. Molecular Medicine Reports.
Crossref
Crossref
Long Zhang, Yong Wang, Dejun Yang, Wenjuan Huang, Pengyan Hao, Sheng Feng, Dietmar Appelhans, Tinghong Zhang & Xingjie Zan. (2019) Shape Effect of Nanoparticles on Tumor Penetration in Monolayers Versus Spheroids. Molecular Pharmaceutics 16:7, pages 2902-2911.
Crossref
Crossref
Rashmi Kumari, Dhanya Sunil, Raghumani S. Ningthoujam & NV Anil Kumar. (2019) Azodyes as markers for tumor hypoxia imaging and therapy: An up-to-date review. Chemico-Biological Interactions 307, pages 91-104.
Crossref
Crossref
Jana Kubíčková, Katarína Elefantová, Lucia Pavlikova, Martin Cagala, Mário Šereš, Peter Šafář, Štefan Marchalín, Kamila Ďurišová, Viera Boháčová, Zdena Sulova, Boris Lakatoš, Albert Breier & Petra Olejníková. (2019) Screening of Phenanthroquinolizidine Alkaloid Derivatives for Inducing Cell Death of L1210 Leukemia Cells with Negative and Positive P-glycoprotein Expression. Molecules 24:11, pages 2127.
Crossref
Crossref
Guoliang Yang, Jia Tian, Chao Chen, Dawei Jiang, Yudong Xue, Chaochao Wang, Yun Gao & Weian Zhang. (2019) An oxygen self-sufficient NIR-responsive nanosystem for enhanced PDT and chemotherapy against hypoxic tumors. Chemical Science 10:22, pages 5766-5772.
Crossref
Crossref
Ning Li, Ling Li, Haiming Wu & Heng Zhou. (2019) Antioxidative Property and Molecular Mechanisms Underlying Geniposide-Mediated Therapeutic Effects in Diabetes Mellitus and Cardiovascular Disease. Oxidative Medicine and Cellular Longevity 2019, pages 1-20.
Crossref
Crossref
Taylor Harding, Linda Baughn, Shaji Kumar & Brian Van Ness. (2019) The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. Leukemia 33:4, pages 863-883.
Crossref
Crossref
Long Zhang, Pengyan Hao, Dejun Yang, Sheng Feng, Bo Peng, Dietmar Appelhans, Tinghong Zhang & Xingjie Zan. (2019) Designing nanoparticles with improved tumor penetration: surface properties from the molecular architecture viewpoint. Journal of Materials Chemistry B 7:6, pages 953-964.
Crossref
Crossref
Pawel Robak, Izabela Drozdz, Janusz Szemraj & Tadeusz Robak. (2018) Drug resistance in multiple myeloma. Cancer Treatment Reviews 70, pages 199-208.
Crossref
Crossref
Jie Yang, Wei Li, Lihua Luo, Mengshi Jiang, Chunqi Zhu, Bing Qin, Hang Yin, Xiaoling Yuan, Xiaoyi Yin, Junlei Zhang, Zhenyu Luo, Yongzhong Du & Jian You. (2018) Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance. Biomaterials 182, pages 145-156.
Crossref
Crossref
Zhaozhou Zhang, Yan Wang & Qi Li. (2018) Mechanisms underlying the effects of stress on tumorigenesis and metastasis (Review). International Journal of Oncology.
Crossref
Crossref
A Besse, S C Stolze, L Rasche, N Weinhold, G J Morgan, M Kraus, J Bader, H S Overkleeft, L Besse & C Driessen. (2017) Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia 32:2, pages 391-401.
Crossref
Crossref
Hong Zhu, Jun Gao, Lei Wang, Ke‑Jian Qian & Li‑Ping Cai. (2018) In�vitro study on reversal of ovarian cancer cell resistance to cisplatin by naringin via the nuclear factor-κB signaling pathway. Experimental and Therapeutic Medicine.
Crossref
Crossref
Mark E. Issa, Farnaz Sedigheh Takhsha, Chandra Sekhar Chirumamilla, Claudina Perez-Novo, Wim Vanden Berghe & Muriel Cuendet. (2017) Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Clinical Epigenetics 9:1.
Crossref
Crossref
Roberto Ronca, Mohammed Benkheil, Stefania Mitola, Sofie Struyf & Sandra Liekens. (2017) Tumor angiogenesis revisited: Regulators and clinical implications. Medicinal Research Reviews 37:6, pages 1231-1274.
Crossref
Crossref
Mark E. Issa, E. M. K. Wijeratne, A. A. L. Gunatilaka & Muriel Cuendet. (2017) Withanolide D Exhibits Similar Cytostatic Effect in Drug-Resistant and Drug-Sensitive Multiple Myeloma Cells. Frontiers in Pharmacology 8.
Crossref
Crossref
Yingchun Qu, Peifang Cong, Chengjiang Lin, Yihui Deng, Jesse Li-Ling & Meixia Zhang. (2017) Inhibition of paclitaxel resistance and apoptosis induction by cucurbitacin B in ovarian carcinoma cells. Oncology Letters 14:1, pages 145-152.
Crossref
Crossref
Pilar de la Puente & Abdel Kareem Azab. (2017) Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma. European Journal of Haematology 98:6, pages 529-541.
Crossref
Crossref
Onat Kadioglu, Jingming Cao, Nadezda Kosyakova, Kristin Mrasek, Thomas Liehr & Thomas Efferth. (2016) Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-factorial multidrug resistance. Scientific Reports 6:1.
Crossref
Crossref
Barbara Muz, Pilar de la Puente, Feda Azab, Micah John Luderer, Justin King, Ravi Vij & Abdel Kareem Azab. (2016) A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma. British Journal of Haematology 173:1, pages 70-81.
Crossref
Crossref
Benny Zhitomirsky & Yehuda G. Assaraf. (2016) Lysosomes as mediators of drug resistance in cancer. Drug Resistance Updates 24, pages 23-33.
Crossref
Crossref
Irene Riz, Teresa S. Hawley & Robert G. Hawley. (2015) KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Oncotarget 6:17, pages 14814-14831.
Crossref
Crossref
B Muz, P de la Puente, F Azab, M Luderer & A K Azab. (2014) Hypoxia promotes stem cell-like phenotype in multiple myeloma cells. Blood Cancer Journal 4:12, pages e262-e262.
Crossref
Crossref